Prospective Observational Study on Predictors of On-treatment Response and Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegylated Interferons in Georgia
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Aug 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.